

# Akihiro Yoshimura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4192877/publications.pdf>

Version: 2024-02-01

20  
papers

662  
citations

933264

10  
h-index

794469

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1138  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593.	1.3	12
2	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	5.8	69
3	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2244-2256.	3.2	75
4	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. <i>Internal Medicine</i> , 2020, 59, 1605-1610.	0.3	3
5	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 227-234.	1.3	17
6	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 108-112.	0.9	10
7	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 450-460.	1.3	18
8	Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. <i>Thoracic Cancer</i> , 2019, 10, 557-563.	0.8	8
9	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 526-532.	0.8	13
10	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1033-e617.	1.9	3
11	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. <i>Cancers</i> , 2019, 11, 365.	1.7	8
12	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. <i>Cancers</i> , 2019, 11, 410.	1.7	34
13	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 450.	1.0	72
14	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1521-1529.	1.3	82
15	A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 459.	1.9	3
16	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	5.8	223
17	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2018, 18, 1241.	1.1	1
18	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. <i>Medicine (United States)</i> , 2018, 97, e12660.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1338-1341.	0.2	8
20	BK virus pneumonia following stem cell transplantation against diffuse large B-cell lymphoma. <i>Respirology Case Reports</i> , 2018, 6, e00348.	0.3	3